#United States #Oklahoma City #Wheeler Bio #ModularCMC #Biologics Manufacturing

Wheeler Bio Launches Redesigned Website

Wheeler Bio, an innovative Contract Development and Manufacturing Organization (CDMO) based in Oklahoma, has recently unveiled its new website, which showcases the company's expanded capabilities in biologics manufacturing. This redesign represents Wheeler Bio's transformation into a fully integrated CDMO, supporting the entire spectrum of biologics development, from gene design to cGMP (Current Good Manufacturing Practice) production.

The updated site is a testament to Wheeler Bio’s evolution. It emphasizes their commitment to high-science, high-touch drug development processes, reflecting the company's comprehensive expertise and advanced technical offerings that serve a diverse range of biologics developers.

Key Features of the New Website

Enhanced User Experience

The redesigned website offers an improved navigation interface to make it easier for biotechnology companies to explore Wheeler Bio’s various services. New sections detail their broad range of capabilities in biologics development, including cell line development, cGMP Drug Substance, and Drug Product manufacturing.

Introduced ModularCMC™ Platform

Central to the updates is the introduction of Wheeler Bio's AI/ML-enabled ModularCMC™ platform. This innovative platform facilitates antibody-based development in a structured, phase-appropriate manner. By employing standardized work packages alongside Quality-by-Design principles, ModularCMC™ increases efficiency and aligns with regulatory expectations, ultimately helping sponsors shorten timelines in drug development for a variety of therapeutic agents, including monoclonal antibodies, multispecifics, Fc-fusions, and antibody-drug conjugates.

Commitment to Client Partnership

In addition to technological advancements, the website strongly outlines Wheeler Bio's philosophy of high-touch engagement with clients. Ensuring access to dedicated project leadership and providing timely and transparent communication is at the heart of their operations. This commitment to client relations enhances the development process, allowing customers to feel confident and informed throughout their journey with Wheeler Bio.

In-Depth Technical Content

Alongside an expansive array of service descriptions, the website features technical content designed to assist biotech firms in evaluating their development and manufacturing strategies. This resource-rich platform aims to support clients in making informed decisions and establishing their own successful paths in biotherapeutics.

Leadership Insights

Wheeler Bio’s Chief Commercial Officer, Sheli Streck, highlighted the importance of this digital upgrade as the company continues to grow and adapt to the industry’s evolving demands. “Our new website is not just a visual enhancement; it's a representation of our integrated services and the scientific depth that supports our partners from discovery stages to cGMP manufacturing,” said Streck.

Wheeler Bio’s dedication to values such as integrity, scientific excellence, and project management sets it apart from other CDMOs, positioning them as a preferred partner in the biotherapeutics sector.

For those interested in exploring these advancements further, visit wheelerbio.com to navigate through their new offerings and comprehensive resources.

About Wheeler Bio

Wheeler Bio aims to accelerate the transition of drug discoveries into clinically impactful solutions. As pioneers in antibody-based therapeutics, they leverage their ModularCMC™ platform to translate concepts into clinical studies efficiently. Their systematic, well-defined work packages ensure that every drug development stage meets industry standards, resulting in high-quality products supported by a detailed Common Technical Document (CTD) for Investigational New Drug Applications (INDs).

Their commitment to cutting-edge technologies and scientific excellence stems from a deeply experienced team dedicated to delivering results that benefit both pharmaceutical partners and patients globally.